Sykes H F, Sim D A, Wong C J, Cassady J R, Salmon S E
Department of Radiation Oncology, Arizona Cancer Center, University of Arizona College of Medicine, Tucson 85724.
Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):641-7. doi: 10.1016/0360-3016(89)90479-3.
In an attempt to determine whether patients treated for breast cancer with radical or modified radical mastectomy and adjuvant chemotherapy benefit from postoperative radiotherapy, 400 women with Stages II-III breast cancer who received adjuvant chemotherapy based on the combination of Adriamycin and Cytoxan were analyzed retrospectively. Prognostic features which predicted a high risk of isolated local-regional relapse were identified. Thirty-eight percent of these patients were also treated with postoperative radiation in addition to adjuvant chemotherapy and were compared to those patients treated only with adjuvant chemotherapy. With a median follow-up of 60 months, 15% of the patients reviewed developed local-regional disease as the first site of relapse without concommitant systemic relapse. When examined univariately, stage of disease, tumor size, nodal status, and estrogen receptor status were strong prognostic variables. Age, cell type, location of tumor within the breast, menstrual status, radiation dose, and type of treatment were not significantly related to isolated local-regional relapse. However, patients who received postoperative radiation were significantly more advanced in their disease condition. When the factors were examined multivariately, the type of treatment along with stage of disease were found to be statistically significant prognostic indicators. About half of the patients were tested for estrogen receptor status. Multivariate analysis performed on this subset of patients showed that estrogen receptor status, type of treatment, and axillary nodal status were significant predictors of the risk of isolated local-regional relapse. This study suggests that patients treated with mastectomy and Adriamycin and Cytoxan-based adjuvant chemotherapy may benefit from postoperative radiation in reducing the risk of isolated local-regional recurrence.
为了确定接受根治性或改良根治性乳房切除术及辅助化疗的乳腺癌患者是否能从术后放疗中获益,对400例Ⅱ-Ⅲ期乳腺癌且接受了基于阿霉素和环磷酰胺联合方案辅助化疗的女性患者进行了回顾性分析。确定了预测孤立局部区域复发高风险的预后特征。这些患者中有38%除辅助化疗外还接受了术后放疗,并与仅接受辅助化疗的患者进行了比较。中位随访60个月时,接受复查的患者中有15%出现局部区域疾病作为首个复发部位,且无同时发生的全身复发。单因素分析时,疾病分期、肿瘤大小、淋巴结状态和雌激素受体状态是强有力的预后变量。年龄、细胞类型、肿瘤在乳房内的位置、月经状态、放疗剂量和治疗类型与孤立局部区域复发无显著相关性。然而,接受术后放疗的患者疾病状况明显更严重。多因素分析这些因素时,发现治疗类型和疾病分期是具有统计学意义的预后指标。约一半的患者检测了雌激素受体状态。对该亚组患者进行的多因素分析表明,雌激素受体状态、治疗类型和腋窝淋巴结状态是孤立局部区域复发风险的显著预测因素。本研究提示,接受乳房切除术及基于阿霉素和环磷酰胺辅助化疗的患者可能从术后放疗中获益,以降低孤立局部区域复发的风险。